RHD Zygosity Determination from Whole Genome Sequencing Data
John Baronas1, Connie M Westhoff2, Sunitha Vege2, Helen Mah1, Maria Aguad1, Robin Smeland-Wagman1, Richard M Kaufman3,6, Heidi L Rehm1,3,4,5, Leslie E Silberstein6, Robert C Green3,5,7 and William J Lane1,3*
- *Corresponding Author:
- William J Lane
Department of Pathology
Brigham and Women’s Hospital and Harvard Medical School
Amory Lab Building 3rd Floor, Rm 3-117
75 Francis Street, Boston, MA 02115, USA
Email: [email protected]
Received date: July 27, 2016; Accepted date: September 15, 2016; Published date: September 19, 2016
Citation: Baronas J, Westhoff CM, Vege S, Mah H, Aguad M, et al. (2016) RHD Zygosity Determination from Whole Genome Sequencing Data. J Blood Disord Transfus 7:365. doi:10.4172/2155-9864.1000365
Copyright: © 2016 Baronas J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In the Rh blood group system, the RHD gene is bordered by two homologous DNA sequences called the upstream and downstream Rhesus boxes. The most common cause of the D− phenotype in people of European descent is a deletion of the RHD gene region, which results in a hybrid combination of the two Rhesus boxes. PCRbased testing can detect the presence or absence of the hybrid box to determine RHD zygosity. PCR hybrid box testing on fathers can stratify risk for haemolytic disease of the fetus and new born in mothers with anti-D antibodies. Red blood cells and genomic DNA were isolated from 37 individuals of European descent undergoing whole genome sequencing as part of the MedSeq Project. A whole genome sequence-based RHD sequence read depth analysis was used to determine RHD zygosity (homozygous, hemizygous, or null states) with 100% agreement (n=37) when compared to conventional RhD serology and PCR-based hybrid box assay.